AbbVie Says Botox Exempt From Medicare Price Negotiations
AbbVie largely backed away from its constitutional challenges to the Inflation Reduction Act's Drug Price Negotiation Program in D.C. federal court Friday, but still insisted that its suite of Botox drugs...To view the full article, register now.
Already a subscriber? Click here to view full article